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Abstract
Immune cells have the capacity to differentiate and proliferate after stimulation through pattern recognition
receptors (PRRs). In the case of potentially autoreactive T-cells, signaling from self molecules through PRRs
can stimulate these cells to attack otherwise healthy tissue leading to autoinflammatory diseases such as
multiple sclerosis. One self molecule that may induce this effect is hyaluronan, a structural polysaccharide
found in the extracellular matrix. We initially hypothesized that low molecular weight hyaluronan, indicative
of injury, could signal through toll-like receptor 2, a PRR, to upregulate Th17 cell differentiation and
proliferation. Naïve CD4+ murine T-cells were isolated and exposed to low and high molecular weight
hyaluronan to determine the molecule’s effect. Surprisingly, our results showed evidence for both hyaluronan
and hyaluronidase II in upregulating T-helper 17 cell differentiation and proliferation. Further research is
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   Immune  cells  have  the  capacity  to  differentiate  and  proliferate  after  
stimulation  through  pattern  recognition  receptors  (PRRs).  In  the  case  of  
potentially  autoreactive  T-­cells,  signaling  from  self  molecules  through  PRRs  can  
stimulate  these  cells  to  attack  otherwise  healthy  tissue  leading  to  
autoinflammatory  diseases  such  as  multiple  sclerosis.  One  self  molecule  that  
may  induce  this  effect  is  hyaluronan,  a  structural  polysaccharide  found  in  the  
extracellular  matrix.  We  initially  hypothesized  that  low  molecular  weight  
hyaluronan,  indicative  of  injury,  could  signal  through  toll-­like  receptor  2,  a  PRR,  
to  upregulate  Th17  cell  differentiation  and  proliferation.  Naïve  CD4+  murine  T-­
cells  were  isolated  and  exposed  to  low  and  high  molecular  weight  hyaluronan  to  
determine  the  molecule’s  effect.  Surprisingly,  our  results  showed  evidence  for  
both  hyaluronan  and  hyaluronidase  II  in  upregulating  T-­helper  17  cell  
differentiation  and  proliferation.  Further  research  is  necessary  to  describe  the  
mechanism  for  this  effect,  as  well  as  to  establish  its  physiological  relevance.    
    







I  would  like  to  thank  my  advisor,  Dr.  Light,  for  all  his  help  in  writing  this  
work.  Also,  I  would  like  to  thank  Drs.  Fischer  and  Maine  for  agreeing  to  review  
my  work  as  members  of  my  thesis  committee.  Furthermore,  I’d  like  to  thank  my  
mentor,  Dr.  Reynolds,  for  his  patience  throughout  our  experiments  and  writing,  
as  well  as  the  current  and  previous  members  of  our  lab,  Theodore  Peterson,  





Table  of  Contents  
Abstract                           i  
Acknowledgements                       ii  
List  of  Figures                        iv  
List  of  Abbreviations                     v  
Introduction                           1  
Materials  &  Methods                     16  
Results                           29  
Discussion                           42  
Conclusion                           55  
Literature  Cited                        57  





List  of  Figures  
Figure  1.  Functions  of  the  innate  immune  system.            12  
Figure  2.  Innate  immune  cells  activate  adaptive  immune  cells.        13  
Figure  3.  Structure  of  hyaluronan.                    14  
Figure  4.  A  diagram  of  Th17  activation  and  differentiation         15  
Figure  5.  Flow  cytometry  analysis  of  cytokine  expression  following        34       
the  differentiation  assay.  
Figure  6.  qPCR  data  of  cytokine  mRNA  expression  following  the      35  
differentiation  assay.  
Figure  7.  ELISA  analysis  of  supernatant  IL-­17A  levels  following  the       36  
differentiation  assay.  
Figure  8.  SDS-­PAGE  analysis  of  hyaluronan  in  the  supernatant        37  
following  the  differentiation  experiment.  
Figure  9.  Flow  cytometry  analysis  of  cytokine  expression  and  staining     38  
following  the  viability  assay.  
Figure  10.  Flow  cytometry  analysis  of  cytokine  expression  following  the     39  
αCD44  treatment.  
Figure  11.  Flow  cytometry  analysis  of  cytokine  expression  following  the   40  
retroviral  transfection.  
Figure  12.  SDS-­PAGE  analysis  of  supernatants  following  the  retroviral   41  
transfection.  





List  of  Abbreviations  
  
AIRE         autoimmune  regulator  
APC         antigen  presenting  cells  
B6         C57BL/6  (wild-­type)  
Chd7         chromodomain-­helicase-­DNA-­binding  protein  7  
CNS         central  nervous  system  
DAMP        danger  associated  molecular  pattern  
EAE         experimental  autoimmune  encephalitis  
ELISA        enzyme  linked  immunosorbent  assay  
FBS         fetal  bovine  serum  
GMCSF      granulocyte  macrophage  colony-­stimulating  factor  
HMW          high  molecular  weight  
Hyal2         hyaluronidase  2  
IFNγ         interferon  gamma  
IL-­17A        interleukin  17A  
IL-­17F        interleukin  17F  
IL-­21         interleukin  21  
IL-­22         interleukin  22  
IL-­23         interleukin  23  
IL-­6         interleukin-­6  
LMW         low  molecular  weight  
LYVE-­1      lymphatic  vessel  endothelial  hyaluronan  receptor  1  
MHC         major  histocompatibility  complex  
MOG         myelin  oligodendrocyte  glycoprotein  
MS         multiple  sclerosis  
OPC         oligodendrocyte  progenitor  
PAMP        pathogen-­associated  molecular  pattern  
PBS         phosphate  buffered  solution  
PBS+         PBS+1%  FBS  
PRR         pattern  recognition  receptor  
qPCR        quantitative  polymerase  chain  reaction  
RORγt      retinoic  acid  orphan  receptor-­gamma  2  
SDS-­PAGE      sodium  dodecyl  sulfate  polyacrylamide  gel  electrophoresis  
TCR         T-­cell  receptor  
TGF-­β        transforming  growth  factor-­beta  
Th1         T-­helper  1  
Th17       T-­helper  17  
Th2         T-­helper  2  
TLR         toll-­like  receptor       
TLR2         toll-­like  receptor  2  
TLR2-­/-­      TLR2  deficient  






The  immune  system,  composed  of  both  innate  and  adaptive  defenses,  
works  to  protect  the  body  from  pathogens,  cancer,  and  foreign  materials  
(Parham,  2009).  Innate  defenses  are  not  typically  specific  to  any  one  pathogen,  
such  as  an  inflammatory  response  provoked  at  the  site  of  microbial  infection  
(Alberts  et  al.,  2015).  Chemical  signals  from  microbes  trigger  the  expression  of  
signaling  peptides  termed  cytokines,  which  modulate  inflammation  at  the  site  of  
infection.  Typically,  body  temperature  rises,  permeability  of  the  nearby  blood  
vessels  increase,  and  vasodilation  occurs  (Parham,  2009).  Chemokines  are  also  
released  and  attract  phagocytic  cells  such  as  macrophages  and  neutrophils.  
These  phagocytes  engulf  and  then  kill  microbes  using  several  toxic  oxygen-­
derived  compounds  (Alberts  et  al.,  2015).    
Innate  immune  cells  use  pattern  recognition  receptors  to  identify  
pathogens.  Most  bacteria  or  pathogen-­derived  molecules  contain  certain  
pathogen-­associated  molecular  patterns  (PAMPs)  (Tang  et  al.,  2012).  These  
patterns  are  recognized  by  pattern  recognition  receptors  (PRRs)  and  reveal  the  
molecule  to  be  dangerous  (Tang  et  al.,  2012).  There  are  five  well  characterized  
classes  of  PRRs:  toll-­like  receptors  (TLRs),  retinoic-­acid-­inducible  gene-­I  like  
receptors,  nucleotide-­binding  domain  and  leucine  rich  repeat  containing  gene  
family  receptors,  C-­type  lectin  receptors,  and  cytosolic  DNA  receptors  (Alberts  et  
al.,  2015).  Different  PRRs  recognize  different  PAMPs.  
In  addition  to  destroying  pathogens,  innate  immune  cells  have  additional  





immune  system,  including  the  complement  system  and  various  physical  barriers  
to  pathogen  entry,  but  these  lay  outside  the  scope  of  this  project.    
Bridging  the  gap  between  the  innate  and  adaptive  immune  cell  types  are  
dendritic  cells  (Sloane  et  al.,  2010).  These  cells  will  phagocytize  microbes  and  
help  activate  adaptive  immune  cells.  Following  phagocytosis,  dendritic  cells  
cleave  microbial  peptides  and  display  them  on  their  surface  along  with  major  
histocompatibility  complex  (MHC)  proteins,  thereby  giving  them  the  name  of  
antigen  presenting  cells  (APCs)  (Parham,  2009).  In  doing  so,  the  APCs  activate  
immature  adaptive  immune  cells,  or  lymphocytes,  residing  in  the  lymph  nodes.  In  
this  activation  process,  discussed  in  greater  depth  later,  adaptive  immune  cells  
recognize  the  antigen  and  MHC  protein  and  begin  differentiating  into  effector  
cells  (Romagnani  et  al.,  2009).    
The  adaptive  immune  system  is  comprised  mostly  of  two  main  classes:  B-­
cells  and  T-­cells,  collectively  called  lymphocytes  (Alberts  et  al.,  2015).  Both  cell  
types  are  responsible  for  remembering  specific  substances,  termed  antigens,  but  
produce  different  immune  responses.  B-­cells  drive  the  humoral  response  by  
producing  proteins  complementary  to  specific  antigenic  determinants,  termed  
antibodies.  (Alberts  et  al.,  2015)  After  activation  with  an  antigen  complimentary  to  
its  B-­cell  receptor,  B-­cells  transform  into  plasma  cells  which  produce  antibodies  
that  are  distributed  through  the  blood  and  lymph  to  bind  to  pathogens  expressing  
the  same  antigen.  These  antibodies  may  neutralize  the  pathogen  directly,  by  
impairing  its  mobility,  or  indirectly,  by  allowing  it  to  be  phagocytized  more  easily  





the  long-­lived  memory  B-­cells  wait  for  stimulation  with  the  same  initial  antigen  
and  will  produce  antibodies  once  again.  In  contrast,  T-­cells  generate  a  cell-­
mediated  response  whereby  they  fill  a  number  of  roles,  ranging  from  the  direct  
killing  of  microbes  by  releasing  cytotoxic  chemicals  to  stimulating  a  greater  
phagocytic  cell  response  by  releasing  pro-­inflammatory  cytokines  or  helping  in  
the  activation  of  B-­cells  (Alberts  et  al.,  2015).  
T-­cells  develop  from  hematopoietic  stem  cells  in  the  bone  marrow.  After  
the  stem  cell  develops  into  a  lymphoid  progenitor  cell,  the  cell  migrates  to  the  
thymus  gland,  where  it  matures  and  becomes  immunocompetent  (Alberts  et  al.,  
2015)  Immunocompetency  refers  to  ability  of  lymphocytes  to  distinguish  between  
self  and  non-­self  cells,  and  thereby  generate  an  immune  response;;  this  vital  
property  means  that  no  cells  from  the  individual  should  trigger  an  immune  
response  against  cells  originating  from  its  host  (self-­cells)(Carpenter  &  Bosselut,  
2010).  However,  errors  in  the  maturation  of  T-­cells  can  lead  to  self-­reactive  T-­
cells  being  created,  which  can  trigger  some  autoimmune  diseases  (Shah  &  
Zuniga-­Pflucker,  2014).    
Initially,  the  progenitor  cells  are  termed  double  negative  because  they  
express  neither  CD4  nor  CD8,  two  receptors  vital  to  T-­cell  activity  (Parham,  
2009).  After  signaling  through  Notch  receptors,  the  progenitor  cells  become  
committed  to  being  T-­cells,  and  transition  to  double  positive  cells  (CD4+CD8+)  
(Carpenter  &  Bosselut,  2010).  Rearrangement  at  the  T-­cell  receptor  (TCR)  locus  
results  in  unique  α  and  β  chains  that  construct  a  TCR  specific  for  a  single  antigen  





transition  to  single  positive  cells  (CD4+CD8-­  or  CD4-­CD8+),  and  then  undergo  
negative  selection.    
In  both  positive  and  negative  selection,  the  cells  are  exposed  to  a  self-­
antigen,  generate  a  signal,  and  the  intensity  of  that  signal  is  evaluated  (Shah  &  
Zuniga-­Pflucker,  2014).  Positive  selection  ensures  that  all  cells  have  a  functional  
T-­cell  receptor  (TCR);;  cells  that  do  not  generate  a  sufficient  signal  are  neglected  
and  allowed  to  die  as  they  would  be  unable  to  generate  a  sufficient  immune  
response  to  an  actual  antigen.  In  negative  selection,  cells  are  forced  to  undergo  
apoptosis  (programmed  cell  death)  if  they  generate  an  abnormally  high  signal;;  
this  oversensitivity  suggests  the  cell  could  be  autoreactive  and  lead  to  an  
autoimmune  response  later  (Carpenter  &  Bosselut,  2010).  Self-­antigens  can  be  
obtained  one  of  two  ways:  they  are  carried  to  the  thymus  by  recirculating  
dendritic  cells  or  are  generated  by  the  thymic  epithelial  cells.  The  transcription  
factor  autoimmune  regulator  (AIRE)  can  induce  thymic  epithelial  cells  to  express  
tissue-­specific  antigens  not  typically  found  in  the  thymus,  so  that  they  can  be  
used  in  for  testing  in  selection  (Shah  &  Zuniga-­Pflucker,  2014).    
As  such,  any  autoreactive  T-­cells  should  be  destroyed  before  ever  leaving  
the  thymus.  However,  errors  in  the  selection  process  can  occur;;  alternatively,  
there  are  some  self-­antigens  that  are  not  induced  by  AIRE  and  are  not  brought  
by  dendritic  cells.  If  this  occurs,  these  antigens  are  not  present  in  the  thymus  
during  negative  selection,  so  T-­cells  cannot  be  tested  for  reactivity  against  these  
antigens.  T-­cells  that  are  reactive  to  these  self-­antigens  cannot  be  identified,  and  





After  selection,  the  immature,  or  naïve,  cells  are  categorized  by  their  
expression  of  the  cellular  markers  CD4  and  CD8  (Jin  et  al.,  2012).  Eventually,  
after  activation  and  proliferation,  the  naïve  CD4-­CD8+  T-­cells  become  cytotoxic  
T-­cells  and  the  naïve  CD4+CD8-­T-­cells  become  helper  or  regulatory  T-­cells  
(Parham,  2009).  Cytotoxic  T-­cells  kill  target  cells,  such  as  cancer  cells  and  virus-­
infected  cells  by  releasing  cytotoxic  chemicals  (Alberts  et  al.,  2015).  T-­helper  
cells  direct  other  immune  cells  to  mount  an  immune  response.    
T-­cells  are  characterized  by  the  CD4  and  CD8  receptors  because  they  are  
crucial  for  the  activation  of  T-­cells.  There  are  two  types  of  MHC  proteins  (I  and  II)  
expressed  on  the  surface  of  APCs  (Alberts  et  al.,  2015).  MHC  protein  I  interacts  
only  with  CD8  and  MHC  protein  II  interacts  only  with  CD4  (Parham,  2009).  Once  
an  APC  has  phagocytized  a  pathogen  and  broken  down  its  proteins,  the  
fragments  will  bind  to  a  MHC  protein;;  MHC  I  binds  to  endogenous  peptides  (i.e.  
viral  peptides),  whereas  MHC  II  will  bind  to  exogenous  peptides,  such  as  viral,  
bacterial,  fungal,  or  parasitic  peptides  (Parham,  2009).  Once  bound,  the  MHC-­
peptide  complex  is  expressed  on  the  exterior  of  the  APC  where  it  can  be  
recognized  by  a  passing  naïve  T-­cell.  The  CD  receptor  on  the  cell  binds  to  the  
MHC  protein,  thereby  bringing  the  peptide  fragment  within  binding  distance  of  the  
T-­cell  receptor  (TCR).  If  the  peptide  fragment  can  bind  to  the  TCR,  the  T-­cell  is  
activated  and  stimulated  to  differentiate  and  proliferate  (Parham,  2009).  The  
peptide  fragment  helps  determine  what  class  of  cell  it  differentiates  into,  so  that  
the  most  effective  immune  response  is  generated.  Figure  2  outlines  the  process  





Of  particular  interest  in  this  project  is  the  T-­helper  subset  (also  called  
CD4+  T-­cells);;  these  cells  interact  with  other  cell  types  directly  (through  cell-­cell  
interactions)  or  release  cytokines  after  being  activated  by  an  APC  (Patel  &  
Kuchroo,  2015).  T-­helper  cells  work  to  direct  other  immune  cells  such  as  
cytotoxic  T-­cells  and  macrophages  to  target  infected  cells  and  antigens  as  well  
as  activate  and  promote  the  release  of  antibodies  by  immature  B-­cells.  Though  
their  approach  to  pathogen  eradication  is  less  direct  than  most  other  cell  types,  
their  effect  is  substantial.  Virtually  all  adaptive  immune  responses  are  directed  by  
CD4+  T-­cells  (Louten,  et  al.,  2009).  
Within  the  CD4+  T-­cell  group,  there  are  several  subsets,  each  with  a  
distinct  role  within  the  body.  After  being  released  from  the  thymus,  the  
nonactivated  CD4+  T-­cells  are  naïve,  or  undifferentiated.  To  activate  the  naïve  
cell,  and  cause  them  to  differentiate  and  release  cytokines,  the  cell  must  first  be  
stimulated  with  cytokines  and  presented  with  an  antigen  (Patel  &  Kuchroo,  2015).  
The  stimulating  cytokines  induce  the  production  of  transcription  factors  by  
binding  to  receptors  which  then  initiate  downsteam  signaling.  Transcription  
factors  are  proteins  that  bind  to  various  regulatory  regions  or  genes  and  promote  
the  differentiation  towards  a  particular  subset.  Some  of  these  subsets  include  T-­
helper  1  (Th1),  T-­helper  2  (Th2),  and  T-­regulatory  (Treg)  cells  (Jin,  et  al.,  2012).  
These  cells  are  identifiable  by  their  expression  of  interferon  gamma  (IFN-­γ),  
interleukin  4,  and  forkhead  box  P3,  respectively.    
One  recently  characterized  subset  is  the  T-­helper  17  cell,  or  Th17  cell.  





interleukin-­6  (IL-­6)  and  transforming  growth  factor-­beta  (TGF-­β)  are  typically  
cited  (Louten  et  al.,  2009).  Differentiation  cannot  occur  without  cytokine  
stimulation.  These  cytokines  trigger  the  expression  of  two  major  transcription  
factors:  signal  transducer  and  activator  of  transcription  3  (STAT3),  and  retinoic  
acid  orphan  receptor-­gamma  2  (RORγt)  (Romagnani  et  al.,  2009).  Once  
differentiated,  the  mature  Th17  cell  is  characterized  by  the  release  of  specific  
cytokines  such  as  interleukin  17A  (IL-­17A),  interleukin  17F  (IL-­17F),  interleukin  
22  (IL-­22),  and  interleukin  21  (IL-­21)  (Louten  et  al.,  2009).  These  pro-­
inflammatory  cytokines  released  by  Th17  cells  are  used  to  mount  an  immune  
response  specifically  against  extracellular  bacteria  (Jin  et  al.,  2012).    
Microbial  products  can  also  affect  CD4+  T-­cell  differentiation  by  signaling  
through  PRRs  (Jin  et  al.,  2012).  Typically,  PRRs  are  thought  of  as  a  part  of  the  
innate  immune  system  and  are  expressed  on  macrophages  and  other  monocytes  
(Tang  et  al.,  2012).  Once  a  monocyte  recognizes  a  PAMP,  it  is  stimulated  to  act.  
However,  PRRs  are  not  restricted  to  innate  immune  cells.  For  example,  TLRs  are  
expressed  on  both  innate  and  adaptive  immune  cells.  TLR  receptors  can  bind  a  
wide  range  of  ligands  ranging  from  double-­stranded  RNA  to  lipopolysaccharides  
(Miranda-­Hernandez  &  Baxter,  2013).  Specifically,  TLR2  is  expressed  on  naïve  
CD4+  T-­cells  as  well  as  Th17  cells  (Bhaskaran  et  al.,  2015).  This  receptor  
typically  binds  to  bacterial  lipoproteins  and  lipoteichoic  acid  from  Gram-­positive  
bacteria  (Miranda-­Hernandez  &  Baxter,  2013).  Signaling  through  the  TLR2  
receptor  could  have  consequences  for  CD4+  T-­cell  differentiation  and  





It  is  of  interest  to  note  that  PRRs  do  not  differentiate  between  self  and  
foreign  materials;;  instead  it  recognizes  the  presence  of  a  PAMP  or  other  danger  
associated  molecular  pattern  (DAMP).  As  such,  it  is  possible  for  self-­molecules  
with  structures  resembling  DAMPs  to  bind  to  TLR2  or  other  PRRs  and  cause  an  
immune  response,  contributing  to  an  autoimmune  disease.  Cases  of  autoimmune  
disorders  with  sterile  inflammation  such  as  multiple  sclerosis  (MS)  may  be  
caused  in  part  by  inappropriate  self-­molecule  recognition  (Hernandez-­Pedro  et  
al.,  2013).  
Multiple  sclerosis  is  a  chronic  inflammatory  disease  in  which  the  immune  
system  attacks  the  myelin  sheath  and  nerve  fibers  of  the  central  nervous  system  
(CNS)  (Jadidi-­Niaragh  &  Mirshafiey,  2011).  Symptoms  can  be  severe,  and  range  
from  blurry  vision,  to  muscle  weakness,  to  paralysis  (Russi  &  Brown,  2015).  
Though  the  symptoms  can  be  treated  with  a  variety  of  medications,  there  is  no  
reversing  the  damage  to  CNS  tissue  nor  safely  impairing  the  destructive  immune  
cells.  As  such,  there  is  no  cure,  and  current  treatments  are  limited  to  symptom  
management.  As  a  disease  that  affects  over  2.3  million  individuals,  there  is  a  
great  need  for  treatments  to  prevent  or  stop  the  inflammation  that  causes  the  
disease  state.    
Evidence  has  implicated  Th17  cells  in  MS  (Goverman,  2009).  Research  
has  found  evidence  that  Th17  cells  and  Th1  cells  are  the  main  immune  cells  
contributing  to  central  nervous  system  inflammation  in  MS  (Rostami  &  Ciric,  
2013).  Th17  cells  and  Th1  cells  can  be  found  infiltrating  central  nervous  system  





healthy  individuals.  Thus,  researchers  inferred  that  the  infiltration  of  Th17  cells  
and  Th1  cells  participate  in  directing  inflammation  in  the  CNS  tissues  with  pro-­
inflammatory  cytokines  (El-­Behi  et  al.,  2011).  
Furthermore,  signaling  through  TLRs  on  Th17  cells  incites  an  immune  
response,  contributing  to  an  increase  in  pathogenic  Th17  cells  in  MS  (Reynolds  
et  al.,  2010).  Pathogenicity  is  the  ability  of  a  cell  to  do  harm,  or  destroy;;  it  is  not  
intrinsically  bad.  For  example,  pathogenic  T-­cells  are  extremely  helpful  during  
infections  as  these  cells  are  more  able  to  fight  off  pathogens  than  typical  Th17  
cells  (Lubberts,  2015).  However,  when  autoreactive  T-­cells  are  activated  and  
become  pathogenic,  a  disease  state  can  occur  in  which  inflammation  is  
heightened  and  more  immune  cells  are  recruited  activated  (Rostami  &  Ciric,  
2013).    
Pathogenic  Th17  cells  can  be  characterized  by  increased  expression  of  
(IFNγ)  or  granulocyte  macrophage  colony-­stimulating  factor  (GMCSF)  along  with  
all  other  typical  cytokines  such  as  IL-­17A  and  IL-­17F  (Reynolds  et  al.,  2010).  
Signaling  through  TLR2  or  with  interleukin-­23  (IL-­23)  can  incite  pathogenesis  in  
Th17  cells  (Lubberts,  2015).  Evidence  shows  that  the  increase  in  TLR2  signaling  
ligands  leads  to  an  increase  in  IL-­17A  and  IL-­22,  indicating  that  there  are  
increased  numbers  of,  or  more  pathogenic,  Th17  cells  (He  et  al.,  2016;;  Nishimori  
et  al.,  2012).  Furthermore,  IL-­17A  leads  to  greater  TLR2  expression,  thereby  
creating  a  positive  feedback  loop.  (Lee  et  al.,  2009)  Other  studies  show  that  
signaling  through  TLR2  also  upregulates  Th17  differentiation,  though  no  





experiments  support  the  role  of  TLR2  as  being  able  to  provoke  an  inflammatory  
Th17  response.  Experimental  autoimmune  encephalitis  (EAE)  (a  murine  model  of  
MS)  studies  demonstrate  a  decrease  in  disease  severity  and  progression  in  
TLR2  deficient  T-­cells  (Reynolds  &  Dong,  2013).      
Thus,  we  know  that  autoreactive  T-­cells  can  initiate  autoimmune  
inflammation  amplified  by  the  induction  of  pathogenicity  in  T-­cells,  which  can  set  
off  a  cycle  of  disease  state  inflammation  leading  to  increased  Th17  cell  
populations  which  leads  back  to  increased  inflammation.  We  are  still  seeking  the  
self-­molecule  that  will  signal  through  TLR2  to  trigger  pathogenesis  in  
autoreactive  T-­cells.  One  clinical  goal  of  this  study  was  to  better  understand  and  
to  prevent  the  onset  of  autoimmune  disorders  from  self-­molecule  signaling  
through  TLRs.  
One  possible  self-­molecule  that  could  aggravate  autoimmune  
inflammation  is  hyaluronan  (its  anionic  form  is  called  hyaluronic  acid),  a  large  
polysaccharide  comprised  of  repeating  disaccharide  units  of  N-­acetyl  
glucosamine  linked  to  glucuronic  acid  by  β  1,3  bonds  (figure  3)  (Humphrey,  
1943).  This  ubiquitous  molecule  is  typically  found  within  synovial  fluid,  skin,  and  
connective  tissues;;  it  binds  to  water  and  is  an  important  gelling  compound  in  the  
extracellular  matrix  (Spinelli  et  al.,  2015).  Receptors  for  hyaluronan  include  
CD44,  which  is  prevalent  in  T-­cells,  and  lymphatic  vessel  endothelial  hyaluronan  
receptor  1  (LYVE-­1)  (Laurent  &  Fraser,  1992).    
Typically,  healthy  tissue  contains  high  molecular  weight  hyaluronan,  which  





relatively  short  lifetime  for  a  structural  molecule,  and  must  travel  through  the  
lymph  system  to  reach  the  liver  for  degradation  (Gomez-­Aristizabal  et  al.,  2016).  
Alternatively,  when  tissue  is  damaged  and  the  risk  of  infection  by  bacteria  is  high,  
hyaluronan  is  broken  into  low  molecular  weight  fragments  of  anywhere  between  
102  –  104  kDa  (Lee-­Sayer,  et  al.  2015).  Prior  research  has  shown  that  hyaluronan  
production  is  heightened  during  inflammation  and  has  confirmed  its  role  in  wound  
healing  (Jiang,  2005).  Hyaluronan  is  also  involved  with  T-­cell  mediated  
autoimmune  disorders  (Back  et  al.,  2005;;  Esser  et  al.,  2012).  There  is  also  some  
speculation  that  hyaluronan  is  involved  with  CD4+  T-­cell  differentiation  (Kuipers  
et  al.,  2015).  Research  has  shown  that  hyaluronan  can  signal  through  TLR2  
(Shimada  et  al.,  2008).  Thus,  there  is  a  possibility  that  hyaluronan  signaling  
through  TLR2  leads  to  an  upregulation  in  Th17  differentiation,  which  in  turn  
amplifies  autoimmune  inflammation.  Figure  4  describes  the  entire  Th17  system:  
an  autoreactive  naïve  T-­cell  is  activated  by  a  self-­antigen  and  stimulated  by  
hyaluronan  signaling  through  TLR2,  leading  to  an  upregulation  of  Th17  
differentiation,  increased  cytokine  production  and  possibly  pathogenicity.      
Here  we  investigate  how  differing  molecular  weights  of  hyaluronan  affect  
Th17  differentiation.  Given  that  high  molecular  weight  hyaluronan  dominates  in  
healthy  body  tissue,  we  expect  this  treatment  to  minimally  influence  Th17  
differentiation.  However,  since  low  molecular  weight  hyaluronan  is  indicative  of  
injury  and  possible  bacterial  infection,  we  expect  this  treatment  to  act  as  an  
endogenous  danger  signal.  In  this  case,  we  expect  that  low  molecular  weight  






Figure  1.  Functions  of  the  innate  immune  system.  Monocytes,  an  immature  
macrophage/dendritic  cell,  can  identify  pathogens  using  PRRs,  and  then  use  






Figure  2.  Innate  immune  cells  activate  adaptive  immune  cells.  A  dendritic  cell  can  
carry  an  antigen  on  MHC  protein  I  or  ll  to  a  naïve  T-­cell  and,  with  stimulatory  
cytokines,  induce  the  T-­cell  to  differentiate  into  a  mature  T-­helper  cell  or  cytotoxic  






Figure  3.  Structure  of  hyaluronan.  Hyaluronan  is  composed  of  N-­acetyl  
glucosamine  and  glucuronic  acid  linked  by  β  1,3  bonds.  High  molecular  weight  
hyaluronan  is  approximately  1x106  kDa,  but  can  be  cleaved  into  smaller  







Figure  4.  A  diagram  of  Th17  activation  and  differentiation.  1.  An  autoreactive  
naïve  T-­cell  will  be  activated  with  signaling  through  the  TCR  with  a  self-­antigen  
and  with  MHC  II  protein  signaling  through  CD4.  2.  Stimulatory  cytokines  IL-­6  and  
TGFβ  also  activate  the  cell.  3.  Stimulation  of  TLR2  by  low  molecular  weight  
hyaluronan  increases  Th17  activation.  4.  After  steps  1-­3,  transcription  factors  
STAT3  and  RORγ  are  expressed,  leading  to  differentiation  and  the  release  of  
cytokines.  Steps  1  and  2  and  imperative  for  T-­cell  differentiation;;  step  3  can  
increase  cytokine  production,  proliferation,  or  pathogenicity  but  differentiation  can  






Materials  &  Methods  
Experimental  Design  
   To  best  determine  the  impact  of  hyaluronan  signaling  through  TLR2  in  
Th17  differentiation,  four  key  experiments  were  performed:  a  differentiation  
assay,  a  viability  assay,  αCD44  treatment,  and  Hyal2  retroviral  transfection.  In  
each  experiment,  naïve  T-­cells  from  wild-­type  and  TLR2  knock-­out  mice  were  
obtained,  treated  with  differing  amounts  and  types  of  hyaluronan,  allowed  to  
differentiate,  and  then  compared.  The  cells  were  analyzed  using  flow  cytometry,  
quantitative  polymerase  chain  reaction  (qPCR)  (mRNA  analysis),  enzyme  linked  
immunosorbent  assay  (ELISA),  or  a  sodium  dodecyl  sulfate  polyacrylamide  gel  
electrophoresis  (SDS-­PAGE).  
Mice  
   Experiments  were  conducted  with  C57BL/6  (B6)  (wild-­type)  and  TLR2  
deficient  (TLR2-­/-­)  mice,  both  of  which  were  obtained  from  Jackson  Laboratories  
(Bar  Harbor,  ME).  The  mice  were  housed  at  Rosalind  Franklin  University  of  
Medicine  and  Science  and  given  free  access  to  water  and  dry  food.  A  12  hour  
light,  12  hour  dark  schedule  was  maintained.  At  6-­10  weeks  of  age,  the  mice  
were  sacrificed  using  carbon  dioxide  and  secondary  cervical  dislocation  under  
protocols  approved  by  the  Institutional  Animal  Care  and  Use  Committee  of  







Naïve  CD4+  T-­cell  Collection  
   Naïve  CD4+  T-­cells  were  isolated  from  female  B6  and  TLR2-­/-­  mice;;  
approximately  3  x  106  cells/mouse  were  expected.  The  wild  type  and  TLR2  
deficient  cells  were  kept  separate  throughout  this  entire  procedure.  After  being  
sacrificed,  the  spleen  and  lymph  nodes  (inguinal,  axillary,  brachial,  and  cervical)  
were  removed.  Both  sets  of  tissue  were  smashed  in  PBS+  (1x  PBS  (phosphate  
buffered  solution,  pH=7.4;;  diluted  from  purchased  10x  stock:  Life  Technologies,  
Carlsbad,  CA)  +  1%  fetal  bovine  serum  (FBS;;  Life  Technologies,  Carlsbad,  CA))  
using  a  3  mL  syringe,  then  filtered  through  mesh.  The  spleen  solution  was  
centrifuged  at  1500  rpm  for  5  minutes  at  4ºC  to  pellet  the  cells.  The  cells  were  
resuspended  in  3  mL/mouse  of  lysing  buffer,  allowed  to  incubate  for  1  minute,  
then  quenched  with  PBS+.  The  spleen  and  lymph  node  solutions  were  combined  
and  pelleted.    
   At  this  point,  one  of  two  protocols  would  be  followed.  One  could  separate  
out  the  CD4+  cells,  stain  them,  and  then  sort  out  the  naïve  T-­cells  using  the  cell  
sorter  machine.  Alternatively,  one  could  use  a  kit  to  sort  out  the  naïve  T-­cells  
using  a  small  magnet.  The  first  protocol,  using  a  cell  sorter,  is  more  expensive  
and  time-­consuming,  but  typically  provides  higher  yields  and  fewer  contaminating  
cells.  The  second  protocol  of  using  a  magnet  is  cheaper  and  quicker,  but  has  
lower  yields  and  often  small  amounts  of  magnetic  beads  or  red  blood  cells  would  
be  mixed  with  the  naïve  T-­cells.  Both  protocols  were  used  for  different  





   To  sort  using  a  cell  sorter,  we  needed  to  first  eliminate  the  CD4-­  cells  to  
decrease  the  volume  of  the  sample  going  in  the  sorter.  After  cells  were  lysed  with  
lysing  buffer  and  pelleted,  they  were  resuspended  in  150  µL/mouse  of  PBS+  and  
15  µL/mouse  of  anti-­CD4-­conjugated  microbeads  (Miltenyi  Biotec,  Auburn,  CA)  
and  incubated  for  15  minutes  at  4ºC  in  the  dark.  The  cells  were  washed,  pelleted,  
resuspended  in  PBS+,  and  filtered  through  a  mesh.  The  cells  were  sorted  on  an  
AutoMacs  cell  seperator  (Miltenyi  Biotec,  Serial#0095)  using  the  positive  
selection  program;;  the  positive  fraction  was  washed  with  PBS+  and  the  negative  
fraction  was  discarded.    
   After  washing  and  pelleting  the  positive  fraction,  the  cells  were  stained  
with  anti-­CD62L-­FITC,  anti-­CD25-­PE,  anti-­CD4-­PerCP,  and  anti-­CD44-­APC  
stains  (all  obtained  from  Biolegend,  San  Diego,  CA).  The  cells  incubated  for  20  
minutes  at  4ºC  in  the  dark,  then  were  washed  with  PBS+,  pelleted,  resuspended  
in  300  µL/mouse  PBS+,  and  filtered  through  a  cell  strainer  mesh.  The  cells  were  
then  sorted  on  the  BD  FACS  Aria  llu  cell  sorter  for  the  CD4+CD62LhighCD25-­
CD44low  fraction,  which  corresponds  to  naïve  CD4+  T-­cells.  After  the  cells  were  
collected,  they  were  immediately  used  in  one  of  the  following  assays.    
   Alternatively,  when  one  was  sorting  using  the  kit  magnet,  we  would  
determine  the  concentration  of  cells  after  lysing  with  the  ACK  lysing  buffer  and  
pelleting.  The  cells  were  resuspended  to  a  concentration  of  1x108  cells/mL  in  
PBS+  and  processed  in  2  mL  or  less  increments.  All  the  following  reagents  were  
from  the  Easy  Sep  mouse  naïve  CD4+  T-­cell  isolation  kit  (Stem  Cell  





and  50  µL/mL  of  CD4+  T-­cell  isolation  cocktail  were  added  to  the  cells  and  
incubated  for  7.5  minutes  at  room-­temperature.  Then,  50  µL/mL  memory  T-­cell  
depletion  cocktail  were  added  to  the  cells  and  incubated  for  2.5  minutes  at  room-­
temperature.  The  streptavidin  RapidSpheres  50001  were  vortexed  and  added  to  
the  cells  at  75  µL/mL  to  incubate  for  another  2.5  minutes.  The  tube  containing  the  
cells  was  then  set  in  the  EasySep  Magnet  (Stem  Cell  Technologies,  Vancouver,  
Canada)  and  incubated  for  2.5  minutes.  The  magnet  and  tube  were  picked  up  
and  the  solution  inside  containing  the  naïve  CD4+  T-­cells  was  carefully  decanted.  
The  cells  were  washed  with  PBS+  and  immediately  used  for  one  of  the  following  
assays.    
Differentiation  Assay  
   This  assay  was  used  to  determine  whether  hyaluronan  of  differing  
molecular  weights  affected  differentiation  rates  of  CD4+  T-­cells.  Naïve  T-­cells  
from  both  wild-­type  and  TLR2  deficient  mice  were  isolated  using  a  cell  sorter  and  
cultured  at  1x106  cells/mL  in  RPMI  1640  (Life  Technologies,  Carlsbad,  CA)  
media  supplemented  with  10%  FBS,  1%  L-­glutamine  (Life  Technologies,  
Carlsbad,  CA),1%  Penicillin/Streptomycin  (Life  Technologies,  Carlsbad,  CA),  
0.1%  β-­mercaptoethanol  (Life  Technologies,  Carlsbad,  CA),  and  0.05%  
gentamicin  (Life  Technologies,  Carlsbad,  CA).  The  cells  were  plated  in  48  well  
plates  that  had  been  incubated  with  1  µg  anti-­CD28  antibodies  (BD,  Franklin  
Lakes,  NJ)  and  1  µg  anti-­CD3  antibodies  (BD,  Franklin  Lakes,  NJ)  overnight  at  
4ºC  and  washed  with  PBS.  All  cells  were  induced  to  differentiate  into  Th17  cells  





(eBioscience,  San  Diego,  CA)  at  5  µg/mL,  and  anti-­IFN-­γ  monoclonal  antibodies  
(eBioscience,  San  Diego,  CA)  at  5  µg/mL.  The  treatments  were  as  follows:  Th17  
(no  additional  components),  Th17+500  µg  low  molecular  weight  hyaluronan  (289  
kDa;;  R&D,  Houston,  TX),  Th17+1000  µg  low  molecular  weight  hyaluronan,  Th17  
+500  µg  high  molecular  weight  hyaluronan(1.35x105  kDa;;  R&D,  Houston,  TX),  
and  Th17  +1000  µg  high  molecular  weight  hyaluronan  in  both  wild-­type  and  
TLR2  KO  cells.    
   The  cells  grew  for  4  days  at  37ºC  with  5%  carbon  dioxide.  On  the  fourth  
day,  the  cells  were  split  1:2  for  flow  cytometry  analysis  and  mRNA  analysis.  
Viability  Assay  
   The  viability  assay  was  used  to  compare  the  amounts  of  dying  cells  with  
different  hyaluronan  treatments.  Immediately  following  the  isolation  of  naïve  T-­
cells  by  cell  sorter,  the  cells  were  divided  and  plated  on  two  plates  that  had  been  
coated  overnight  with  1  µg  anti-­CD28  antibodies  and  1  µg  anti-­CD3  antibodies  at  
4ºC  and  washed  with  PBS.  All  cells  were  induced  to  differentiate  into  Th17  cells  
with  mIL-­6  at  20  ng/mL,  TGF-­β  at  3  ng/mL,  anti-­IL-­4  monoclonal  antibodies  at  5  
µg/mL,  and  anti-­IFN-­γ  monoclonal  antibodies  at  5  µg/mL.  The  treatments  were  
as  follows:  Th17  (no  additional  components),  Th17  +1000  µg  low  molecular  
weight  hyaluronan,  and  Th17  +1000  µg  high  molecular  weight  hyaluronan  in  both  
wild-­type  and  TLR2  KO  cells.    
   The  cells  grew  for  4  days  at  37ºC  with  5%  carbon  dioxide.  On  the  fourth  
day,  the  cells  were  taken  for  flow  cytometry  analysis.  The  first  plate  of  cells  was  





The  second  plate  of  unlabeled  cells  was  stained  with  Annexin  V  
(fluoresces  in  the  APC  channel)  for  apoptosis  peptides  and  7-­AAD  (fluoresces  in  
the  PerCP  channel)  for  exposed  DNA,  two  common  markers  of  cellular  death.  
The  cells  were  pelleted  and  resuspended  at  106  cells/mL  in  Annexin  V  binding  
buffer  (BD,  Franklin  Lakes,  NJ);;  105  cells  were  moved  to  a  new  tube  for  staining.  
Next,  5  µL  each  of  Annexin  V  stain  (BD,  Franklin  Lakes,  NJ)  and  7-­AAD  stain  
(BD,  Franklin  Lakes,  NJ)  was  added  to  the  cells  and  allowed  to  incubate  for  20  
minutes  at  room-­temperature  in  the  dark.  A  volume  of  400  µL  of  Annexin  V  
binding  buffer  was  added  to  each  tube  to  stop  the  staining.    
   All  the  samples  were  run  on  the  flow  cytometer  (BD  LSR  ll)  and  the  
fluorescence  emitted  by  the  stain  in  each  sample  measured.  The  data  were  then  
analyzed  using  FlowJo  v10  (FlowJo,  LLC,  Ashland,  Oregon)  software.    
CD44  Antibody  Treatment  
   The  differentiation  assay  was  repeated  with  anti-­CD44  antibodies  to  
prevent  hyaluronan  signaling  through  CD44.  Both  WT  and  TLR2-­/-­  cells  were  
sorted  using  the  magnet  and  the  cells  were  plated  with  the  stimulating  cytokines,  
as  described  previously.  Two  wells  of  the  following  conditions  were  prepared:  
Th17,  Th17  +1000  µg  low  molecular  weight  hyaluronan,  and  Th17  +1000  µg  high  
molecular  weight  hyaluronan  in  both  WT  &  TLR2-­/-­  cell  types  (12  wells  total).  
Then,  one  well  of  each  condition  was  treated  with  5  µg/mL  of  anti-­CD44  





   The  cells  were  allowed  to  grow  for  5  days  at  37ºC  with  5%  carbon  dioxide.  
Following  this,  the  cells  were  stimulated  and  stained  for  flow  cytometry  analysis  
as  described  later.    
Creation  of  Hyal2  Retroviral  Construct  
   The  Hyal2  sequence  was  cloned  out  of  Th17  cDNA  using  a  Phusion  
enzyme  kit  (Fisher,  Hampton,  NH).  The  primers  used  had  Agel  and  Xhol  
restriction  enzymes  sites  on  the  start  and  end  of  the  sequence,  respectively.  The  
primer  sequences  were  as  follows:  AGAACCGGTATGCGGGCAGGACTAGGT  
(forward)  and  TCGCTCGAGTCATAAGGTCCAGGTGAG  (reverse).  The  Hyal2  
sequence  was  then  polyA-­tailed  and  ligated  into  the  pGEM-­T  Easy  Vector  
(Promega,  Madison,  WI).  The  Hyal2-­pGEM-­T  Easy  construct  was  sequenced  by  
Northwestern  University’s  NUSeq  Core  Facility  (Chicago,  IL).  Once  the  sequence  
was  confirmed,  the  Hyal2  sequence  was  cut  out  using  Agel  and  Xhol  cut  sites  
and  ligated  into  the  retroviral  pCmmp  iRES  GFP  vector.  
Retroviral  Transfection  
   Naïve  CD4+  T-­cells  were  transfected  with  the  Hyal2  construct  to  
overexpress  Hyal2.  First,  viral  particles  were  produced  by  PLAT-­E  cells  after  a  
calcium  phosphate  transfection.  Media  was  aspirated  off  6  plates  of  PLAT-­E  cells  
(4.5x106  cells/plate)  and  replaced  with  10  mL  DMEM+  (DMEM  (Life  
Technologies,  Carlsbad,  CA)  +10%  FBS,  1%  Penicillin/Streptomycin,  1%  L-­
glutamine)  with  1x  chloroquine.  Two  mixtures  of  10  µg  of  DNA  per  plate  of  PLAT-­
E  cells  (either  Hyal2  construct  or  empty  pDES  vector)  in  0.25  M  CaCl2  (diluted  





Carlsbad,  CA)  and  incubated  for  5  minutes  at  room  temperature.  Then,  the  
mixture  was  added  dropwise  to  the  plates  of  cells;;  each  mixture  was  used  on  3  
plates.  The  plates  incubated  at  37ºC  with  5%  CO2  for  6  hours,  then  washed  with  
fresh  DMEM+  and  allowed  to  grow  for  another  48  hours.    
   After  the  48  hour  incubation,  6  wells  of  wild-­type  naïve  T-­cells  were  plated  
as  detailed  above.  No  hyaluronan  was  added  at  that  time.  Also  after  the  48  hour  
incubation,  the  supernatant  (filled  with  copies  of  the  retrovirus)  was  pulled  off  the  
PLAT-­E  cells  and  spun  at  8000  g  at  4ºC  overnight.  The  media  was  aspirated  and  
the  viral  pellets  resuspended  in  a  quarter  of  the  original  volume  of  RPMI+  with  8  
ng/mL  polybrene.  The  naïve  CD4+  T-­cells  were  spun  down,  aspirated,  and  
resuspended  in  1  mL  of  viral  mixture;;  each  viral  mixture  was  used  to  treat  half  the  
wells.  The  naïve  T-­cells  were  centrifuged  at  1800rpm  for  65  minutes  at  30ºC  with  
low  brake.  The  cells  were  then  washed  with  fresh  RPMI+  and  were  treated  with  
hyaluronan.  The  following  conditions  were  set  up:  Th17,  Th17  +1000  µg  low  
molecular  weight  hyaluronan,  and  Th17  +1000  µg  high  molecular  weight  
hyaluronan  with  both  Hyal2  and  empty  vector  transfection  treatments.    
   The  cells  were  allowed  to  grow  for  another  2  days,  then  the  supernatants  
were  taken  for  SDS-­PAGE  analysis  and  the  cells  taken  for  flow  cytometry  
analysis  as  detailed  above.    
Flow  Cytometry  Analysis  
   The  cells  saved  from  the  differentiation  assay  were  analyzed  for  cytokine  
production.  On  the  fourth  day  following  the  start  of  the  differentiation  assay,  the  





ionomycin  (Sigma-­Aldrich,  St.  Louis,  MO),  1  µL  Brefeldin-­A  (eBioscience,  San  
Diego,  CA),  and  0.1  µL  PMA  (Sigma-­Aldrich,  St.  Louis,  MO)  were  added  to  each  
well.  The  cells  were  allowed  to  grow  for  an  additional  5  hours  and  then  they  were  
transferred  to  tubes  and  pelleted.    
   The  cells  were  resuspended  in  30%  Fc  Block  in  1x  FACS  (0.1%  bovine  
serum  albumin  (BSA;;  Sigma-­Aldrich,  St.  Louis,  MO),  0.05  mM  ethylenediamine  
tetraacetic  acid  (EDTA;;  VWR,  Radnor,  PA),  1x  sodium  azide  (Sigma-­Aldrich,  St.  
Louis,  MO)  in  PBS)  buffer  and  allowed  to  incubate  for  15  minutes  at  room  
temperature.  The  cells  were  washed  with  1  mL  of  FACS  buffer  and  pelleted,  then  
fixed  with  IC  Fixation  buffer  (eBioscience,  San  Diego,  CA))  for  20  minutes  at  4ºC  
in  the  dark.  The  cells  were  washed  with  1  mL  of  permeabilization  buffer  
(eBioscience,  San  Diego,  CA),  pelleted,  then  resuspended  in  IL-­17A-­PE  
(eBioscience,  San  Diego,  CA)  and  IFN-­γ-­APC  (BD,  Franklin  Lakes,  NJ)  stains  
diluted  in  permeabilization  buffer.  The  cells  incubated  for  30  minutes  at  4ºC  in  the  
dark,  then  were  washed  with  permeabilization  buffer  and  pelleted.  The  samples  
were  resuspended  in  4%  paraformaldehyde.    
   The  cells  were  then  run  on  the  flow  cytometer  (BD  LSR  ll)  and  the  
fluorescence  emitted  by  the  stain  in  each  sample  measured.  The  data  were  then  
analyzed  using  FlowJo  v10  (FlowJo,  LLC,  Ashland,  Oregon)  software.    
mRNA  Analysis  
   Cells  saved  from  the  differentiation  assay  were  analyzed  for  relative  
amounts  of  cytokine  and  transcription  factor  mRNA.  On  the  fourth  day  following  





to  a  new  plate  that  had  been  incubated  with  anti-­CD3  antibodies  overnight  at  
4ºC.  The  cells  were  allowed  to  grow  for  an  additional  2  hours,  then  they  were  
transferred  to  microcentrifuge  tubes  and  pelleted.  Then,  the  cells  were  
resuspended  in  Trizol  (Life  Technologies,  Carlsbad,  CA).  Next,  chloroform  was  
added  and  the  sample  was  centrifuged  at  13,300  rpm  for  15  minutes  at  4ºC  in  a  
microcentrifuge.  The  sample  will  have  separated  into  two  distinct  layers  within  
the  tube;;  the  top  layer  was  carefully  pulled  off  and  transferred  to  a  new  tube.  The  
bottom  layer  can  be  discarded.  Then,  ice-­cold  -­20ºC  isopropanol  was  added  to  
the  sample  and  centrifuged  at  the  same  conditions,  except  the  spin  time  was  only  
10  minutes.  The  sample  was  decanted  carefully,  to  avoid  disturbing  the  RNA  
pellet  and  washed  with  70%  ethanol  in  water.  The  sample  was  centrifuged  was  
centrifuged  at  the  same  conditions,  except  the  spin  time  was  only  5  minutes.  
Again,  the  sample  was  decanted  carefully,  then  the  pellet  was  allowed  to  dry  
completely.  The  RNA  pellet  was  resuspended  in  11  µL  of  nuclease-­free  water.    
   Next,  the  RNA  was  made  into  cDNA,  both  to  improve  the  stability  of  the  
sample  and  to  allow  PCR  to  be  run  on  the  sample.  A  volume  of  10.5  µL  of  each  
sample’s  RNA  was  denatured  in  the  thermocycler  (Biorad,  C1000  Touch,  
CT009882)  using  the  program  as  follows:  65ºC  for  6  minutes,  hold  at  4ºC.  Next,  
4  µL  of  5x  FS  buffer  (Invitrogen,  Carlsbad,  CA),  2  µL  DTT  (Invitrogen,  Carlsbad,  
CA),  1  µL  of  dNTPs,  1  µL  oligos  (Invitrogen,  Carlsbad,  CA),  0.5  µL  RNAse  
inhibitor  (Invitrogen,  Carlsbad,  CA),  and  1  µL  M-­MLV  (Life  Technologies,  
Carlsbad,  CA)  was  added  to  each  sample.  The  samples  were  placed  in  a  





minutes,  hold  at  12ºC.  The  samples  were  then  diluted  with  80  µL  of  nuclease-­
free  water.    
   Finally,  qPCR  was  run  on  the  samples  to  determine  the  relative  amounts  
of  cytokine/transcription  factor  mRNA  present.  A  volume  of  5  µL  per  well  of  cDNA  
was  pipetted  into  a  96  well  qPCR  plate,  with  6  wells  for  each  sample  (each  
sample  had  each  gene  run  in  duplicate).  Then,  12.5  µL  of  SYBR  Green  (Life  
Technologies,  Carlsbad,  CA),  5.5  µL  of  water,  and  1  µM  primers  (either  Actin,  IL-­
17A,  or  RORyt)  were  added  to  each  well.  The  plate  was  placed  in  the  real-­time  
PCR  machine  (ThermoFisher,  7500  Real  Time  PCR  Machine,  27550150)  was  
the  following  program  run:  95ºC  for  10  minutes,  then  40  cycles  alternating  
between  95ºC  for  15  seconds  and  62ºC  for  1  minute,  then  95ºC  for  15  seconds,  
60ºC  for  1  minute,  95ºC  for  30  seconds,  and  then  hold  at  60ºC.    
ELISA  Analysis  
   The  cell  supernatants  saved  from  the  differentiation  assay  samples  were  
analyzed  for  cytokine  production.  A  96  well  ELISA  plate  was  coated  with  IL-­17A  
capture  antibodies  (BD,  Franklin  Lakes,  NJ)  diluted  1:1000  with  PBS  overnight  at  
4ºC.  The  plate  was  washed  twice  with  washing  buffer  (1xPBS+0.5%  Tween-­20)  
on  the  ELISA  plate  washer  (BioTek  Instruments;;  Model  #  405LSRS;;  Serial  
#13041015)  then  blocked  with  blocking  buffer  (1xPBS+10%  FBS)  for  1  hour  at  
room  temperature.  The  plate  was  washed  three  times  on  the  ELISA  plate  washer  
with  washing  buffer  and  the  standards  and  samples  added.  The  standards  were  
plated  in  duplicate,  and  had  concentrations  ranging  from  25ng/mL-­0.024ng/mL.  





plate  incubated  at  37ºC  for  3  hours,  and  then  was  washed  6  times  on  the  ELISA  
plate  washer  with  washing  buffer.  The  plate  was  then  incubated  with  IL-­17A  
detection  antibodies  (BD,  Franklin  Lakes,  NJ)  diluted  1:1000  with  blocking  buffer  
for  1  hour  at  room  temperature.  The  plate  was  washed  6  times  on  the  ELISA  
plate  washer  with  washing  buffer  and  incubated  with  horseradish  peroxidase  
(Vector  Labs,  Burlingame,  CA)  diluted  1:2000  with  blocking  buffer  for  30  minutes  
at  room  temperature  in  the  dark.  The  plate  was  washed  6  times  on  the  ELISA  
plate  washer  with  washing  buffer  and  incubated  with  ELISA  substrate  (Sigma-­
Aldrich,  St.  Louis,  MO)  until  the  color  development  was  complete,  approximately  
15  minutes.  The  reaction  was  stopped  by  addition  of  8.0  M  sulfuric  acid  and  the  
absorbance  of  each  well  read  at  492  nm  by  a  spectrophotometer  (Molecular  
Devices,  Spectra  Max  Plus  384).  A  4-­parameter  fit  standard  curve  was  
constructed  and  used  to  determine  the  concentration  of  each  of  the  samples.    
SDS-­PAGE  Analysis  
   The  supernatants  of  the  retrovirally  transfected  cells  were  run  on  a  SDS-­
PAGE  to  determine  if  the  overexpression  of  Hyal2  resulted  in  the  cleavage  of  
hyaluronan.  An  8%  SDS-­PAGE  gel  (all  resolving  gel-­no  stacking  gel)  was  made.  
Approximately  30  µL  of  cell  supernatant  or  hyaluronan  standard  was  loaded  on  
the  gel.  Then,  the  gel  was  run  at  120  V  for  4-­5  hours.  Next,  it  was  fixed  in  a  
solution  of  50%  methanol,  10%  acetic  acid,  and  fixative  enhancer  (Biorad,  
Hercules,  CA)  for  20  minutes,  washed  with  water,  and  stained  overnight  with  
0.005%  Stains-­all  (Sigma-­Aldrich,  St.  Louis,  MO).  Finally,  the  gel  was  washed  






   Two-­tailed  t-­tests  were  conducted  to  determine  if  there  were  significant  
differences  between  conditions.  A  P-­value  of  less  than  or  equal  to  0.05  was  
considered  significant.  Three  replicates  were  needed  to  determine  significance  
for  all  experiments  except  qPCR  data;;  the  data  collection  software  is  able  to  
calculate  standard  deviation  for  two  replicates,  allowing  us  to  use  a  t-­test.  Not  all  








   I  first  determined  whether  the  presence  of  low  molecular  weight  
hyaluronan  would  upregulate  Th17  differentiation  using  the  differentiation  assay.  
Figures  5-­7  show  the  results  of  the  flow  cytometry,  qPCR,  and  ELISA  analyses.  
These  analysis  procedures  were  used  to  assess  the  percentage  of  intercellular  
cytokine  positive  cells,  relative  cytokine  and  transcription  factor  mRNA  
expression,  and  amount  of  cytokines  released  into  the  cellular  supernatant  
respectively.  Assuming  our  hypothesis  is  correct,  and  low  weight  hyaluronan  
signals  through  TLR2  to  upregulate  Th17  differentiation  and  proliferation,  we  
expected  to  see  an  increase  in  Th17  cells  between  the  WT  control  and  
hyaluronan  treatments,  but  see  no  difference  between  TLR2-­/-­  controls  and  
treatments.    
We  first  determined  the  percent  of  Th17  cells  present  in  our  samples.  After  
allowing  the  cells  to  proliferate,  each  sample  contained  between  1-­2  x  106  cells.    
The  IL-­17A+IFNγ-­  fraction  in  the  flow  cytometry  analysis  corresponded  to  the  
Th17  population  (Figure  5).  The  other  remaining  cells  were  dead  or  
undifferentiated.  The  high  concentration,  low  molecular  weight  hyaluronan  
treatment  provided  the  greatest  increase  in  Th17  cells  when  compared  to  the  
control  (15.6%  and  12.2%  in  WT  and  TLR2-­/-­,  respectively).  However,  the  high  
molecular  weight  hyaluronan  treatment  caused  a  similar  increase  in  Th17  





samples  were  lower  than  in  WT  samples,  but  an  increase  in  concentration  was  
still  seen  between  the  control  and  hyaluronan  treatments.  
Next  we  evaluated  the  relative  expression  of  mRNA  of  two  key  Th17  
produced  molecules  to  judge  the  extent  of  Th17  differentiation.  The  relative  
mRNA  expression  of  IL-­17A  and  RORγt  compared  to  actin  is  shown  in  Figure  6.  
The  expression  of  IL-­17A  was  higher  in  the  WT  samples  indicating  that  there  
were  more  Th17  cells,  as  we  expected  based  on  our  hypothesis.  Furthermore,  
the  hyaluronan  samples  had  greater  IL-­17A  expression  than  the  respective  
controls.  There  was  some  elevation  of  RORγt  expression  in  the  WT  high  
molecular  weight  hyaluronan  treatments,  but  these  results  were  less  clear-­cut.    
We  then  evaluated  the  level  of  IL-­17A  in  the  cellular  supernatant  using  an  
ELISA  to  judge  the  extent  of  Th17  differentiation.  The  levels  of  IL-­17A  protein  in  
the  cellular  supernatant  showed  a  similar  trend  as  RORγt  mRNA  (Figure  7).  
Though  the  WT  samples  seemed  to  have  had  slightly  higher  levels  of  IL-­17A  
production,  and  the  hyaluronan  treatments  had  higher  expression  than  the  
control,  there  was  no  significant  difference  like  in  the  flow  cytometry  results.  
Finally,  the  cellular  supernatants  were  analyzed  for  any  change  in  
hyaluronan  composition.  The  stock  high  and  low  molecular  weight  hyaluronan  
were  compared  to  the  supernatants  of  Th17  and  high  molecular  weight  condition  
using  a  SDS-­PAGE  analysis  (Figure  8).  It  appeared  as  though  the  Th17  cells  
were  digesting  the  high  molecular  weight  hyaluronan  into  low  molecular  weight  







   After  establishing  hyaluronan  treatments  resulted  in  the  upregulation  of  
Th17  differentiation,  I  next  determined  whether  hyaluronan  treatments  would  lead  
to  greater  cell  viability.  Figure  9  shows  the  results  of  apoptosis  associated  
cellular  marker  staining  analyzed  by  flow  cytometry.  If  our  hypothesis  is  correct,  
we  would  expect  the  lowest  number  of  dying  (7-­AAD+AnnexinV+)  cells  between  
the  control  and  hyaluronan  treated  WT  cells,  with  no  difference  in  the  TLR2-­/-­  
cells.    
   The  first  set  of  staining  repeated  the  differentiation  assay  (Figure  9)  to  
show  that  the  upregulation  of  Th17  differentiation  was  still  present.  The  same  
trends  were  still  evident;;  i.e.,  hyaluronan  treatments  upregulated  Th17  
differentiation  and  the  WT  cells  had  a  higher  level  of  Th17  differentiation  than  
TLR2-­/-­.  There  also  was  a  smaller  difference  between  the  WT  and  TLR2-­/-­  cells  
compared  to  what  was  seen  in  the  differentiation  assay,  indicating  that  the  cells  
may  have  been  over  activated.    
   A  second  set  of  staining  with  7-­AAD  and  Annexin  V  (in  the  PerCP  and  
APC  channels  respectively)  was  used  to  visualize  apoptosis  associated  proteins  
and  exposed  DNA  (Figure  9).  Hyaluronan  treatments  lowered  the  fraction  of  7-­
AAD+AnnexinV+  cells,  indicating  that  there  was  greater  viability.  However,  there  








   Because  previous  experiments  in  our  lab  showed  some  upregulation  of  
Th17  differentiation  and  proliferation  in  the  TLR2-­/-­  mice  with  hyaluronan  
treatment,  we  needed  to  isolate  the  role  of  TLR2.  The  CD44  receptor,  present  in  
naïve  and  Th17  cells,  can  also  bind  fragmented  hyaluronan  and  transduce  a  
signal  (Banerji  et  al.,  1999).  To  prevent  CD44  signaling  from  interfering  with  
TLR2  signaling,  the  cells  were  treated  with  neutralizing  αCD44  antibodies.  These  
antibodies  bind  to  CD44  receptors  and  prevent  the  transduction  of  any  signal.  
Figure  10  shows  the  effect  of  this  treatment  on  Th17  differentiation.  If  the  
upregulation  of  Th17  differentiation  is  mediated  solely  by  TLR2  signaling,  there  
should  be  no  difference  between  αCD44  untreated  and  treated  conditions.  If  this  
effect  is  regulated  by  TLR2  and  CD44  signaling,  TLR2-­/-­  treated  cells  should  
show  no  differences  between  the  control  and  hyaluronan  treatment.    
   The  differentiation  assay  was  repeated  (Figure  10)  to  confirm  the  cells  
were  still  behaving  the  same  way.  Surprisingly,  there  was  no  difference  between  
WT  control  and  hyaluronan  samples  this  time;;  however,  it  also  appeared  that  
some  cells  died  in  the  hyaluronan  treatments.  This  may  have  been  caused  by  
some  external  factor,  possibly  in  the  initial  cell  sorting,  which  impaired  the  WT  
cell  growth.  Yet  the  TLR2-­/-­  cells  experienced  the  same  trends  as  before.    
   The  αCD44  treated  cells  still  showed  upregulation  of  Th17  differentiation  
in  both  WT  and  TLR2-­/-­  samples  (Figure  10).  For  both  cell  types,  Th17  





moderately  upregulated  by  high  molecular  weight  hyaluronan,  meaning  the  
αCD44  treatment  had  no  effect  on  the  differentiation  trends.    
Retroviral  Transfection  
   Because  there  was  Th17  upregulation  by  high  molecular  weight  
hyaluronan,  we  chose  to  investigate  the  mechanism  of  this  in  greater  detail.  As  
shown  in  figure  11,  the  high  molecular  weight  hyaluronan  that  was  added  to  
naïve  T-­cells  was  broken  down  into  smaller  fragments.  We  hypothesized  that  
naïve  T-­cells  or  Th17  derived  hyaluronidase  II  (Hyal2)  digests  the  high  molecular  
weight  hyaluronan  into  lower  molecular  weight  fragments,  which  then  upregulate  
Th17  differentiation.  To  test  this,  we  transfected  naïve  T-­cells  with  a  plasmid  to  
overexpress  Hyal2,  then  added  hyaluronan  and  analyzed  Th17  differentiation  
through  flow  cytometry.  If  this  proposed  mechanism  is  accurate,  we  expected  to  
see  greater  Th17  differentiation  in  the  overexpressing,  high  molecular  weight  
condition  compared  to  the  control  high  molecular  weight  condition.  In  addition,  no  
difference  should  be  seen  between  control  and  overexpressing  low  molecular  
hyaluronan  conditions.    
   The  retroviral  transfection  was  successful,  as  seen  by  high  percentages  of  
GFP+,  or  plasmid  containing,  cells  (Figure  11).  However,  there  was  substantial  
cell  death  in  all  conditions,  indicating  that  the  procedure  was  too  stressful  for  the  
cells.  Unfortunately,  high  cell  death  obscured  the  effect  of  increased  Hyal2  and  
hyaluronan  on  Th17  differentiation.  SDS-­PAGE  analysis  (Figure  12)  confirms  that  
high  molecular  weight  hyaluronan  digestion  was  higher  in  the  Hyal2  






Figure  5.  Flow  cytometry  analysis  of  cytokine  expression  following  the  
differentiation  assay.  There  was  a  significant  difference  between  the  WT  Th17  
and  both  the  high  concentration  low  molecular  weight  (LMW)  and  high  molecular  
weight  (HMW)  hyaluronan  treatments  (n  =3,  P  ≤  0.05).  No  significant  difference  







Figure  6.  qPCR  data  of  cytokine  mRNA  expression  following  the  differentiation  
assay.  There  was  a  significant  difference  in  IL-­17A  expression  between  WT  Th17  
and  both  high  molecular  weight  hyaluronan  treatments  (n  =  2,  P  ≤  0.05).  
Furthermore,  all  samples  except  the  high  concentration,  low  molecular  weight  
hyaluronan  treatments  showed  significant  differences  between  WT  and  TLR2-­/-­  















Figure  7.  ELISA  analysis  of  supernatant  IL-­17A  levels  following  the  differentiation  
assay.  There  was  a  significant  difference  between  some  samples,  such  as  WT  
Th17  and  the  low  molecular  weight  hyaluronan  conditions  (n  =  3,  P  ≤  0.05).  










Figure  8.  SDS-­PAGE  analysis  of  hyaluronan  in  the  supernatant  following  the  
differentiation  experiment.  Control  samples  of  low  and  high  molecular  
hyaluronan,  that  have  never  been  incubated  with  cells,  are  to  the  left.  
Supernatant  from  WT  Th17  and  Th17  +1000  HMW  hyaluronan  are  to  the  right.  
High  molecular  weight  hyaluronan  treated  cellular  supernatant  contained  lower  
weight  fragments.      







Figure  9.  Flow  cytometry  analysis  of  cytokine  expression  and  staining  following  
the  viability  assay.  There  was  a  decrease  in  7-­AAD+AnnexinV+  cells  with  the  
hyaluronan  treatment,  indicating  that  there  was  a  decrease  in  the  number  of  







Figure  10.  Flow  cytometry  analysis  of  cytokine  expression  following  the  αCD44  
treatment.  The  untreated  WT  cells  do  not  follow  the  previously  observed  trend,  
possibly  caused  by  an  issue  with  the  naïve  cell  sorting.  There  was  no  difference  







Figure  11.  Flow  cytometry  analysis  of  cytokine  expression  following  retroviral  
transfection.  GFP  expression  confirmed  the  percentage  of  cells  transfected.  No  






Figure  12.  SDS-­PAGE  analysis  of  supernatants  following  retroviral  transfection.  
Cellular  supernatant  from  the  Hyal2  overexpressing  high  molecular  weight  
hyaluronan  treated  samples  showed  greater  digestion  of  hyaluronan,  as  







Our  main  hypothesis  was  that  hyaluronan  signals  through  TLR2  to  
upregulate  Th17  differentiation.  More  specifically,  we  initially  thought  that  low  
molecular  weight  hyaluronan,  which  is  an  indication  of  a  wound  or  injury,  would  
upregulate  Th17  differentiation.  However,  our  initial  results  of  the  differentiation  
assay  were  not  consistent  with  this  hypothesis.  Surprisingly,  high  molecular  
weight  hyaluronan,  which  is  the  normal  state  of  hyaluronan  in  the  body,  also  
upregulated  Th17  differentiation.  Upon  further  examination,  we  found  that  the  
high  molecular  weight  hyaluronan  sample  cellular  supernatant  also  contained  low  
molecular  weight  hyaluronan.    
As  such,  we  revised  our  hypothesis:  Th17  cells  express  Hyal2  which  
cleaves  high  molecular  weight  hyaluronan  into  molecular  weight  hyaluronan,  
which  then  upregulates  Th17  differentiation  by  signaling  through  TLR2.  Our  
results  provide  evidence  that  supports  this  hypothesis.  
Differentiation  Assay  
The  flow  cytometry  results  support  our  hypothesis  that  low  molecular  
weight  hyaluronan  upregulates  Th17  differentiation.  However,  it  also  shows  that  
there  was  an  upregulation  of  Th17  differentiation  by  high  molecular  weight  
hyaluronan.  This  was  unexpected,  as  high  molecular  weight  hyaluronan  is  
common  within  the  body  and  is  not  indicative  of  injury,  as  is  the  case  with  low  
molecular  weight  hyaluronan  (Jiang,  2005).  Furthermore,  high  molecular  weight  
hyaluronan  travels  through  the  lymph  system  to  the  liver  where  it  is  then  





they  likely  interact  with  hyaluronan,  however  there  is  no  evidence  to  suggest  it  
upregulates  Th17  differentiation  in  the  lymph.  Previous  research  has  shown  that  
naïve  T-­cells  require  exposure  to  polarizing  cytokines  to  initiate  Th17  
differentiation,  so  signaling  by  hyaluronan  alone  is  likely  unable  to  induce  
differentiation  (Reynolds  &  Dong,  2013).  
The  upregulation  of  Th17  differentiation  by  high  molecular  weight  
hyaluronan  may  be  explained  by  examining  the  results  from  the  SDS-­PAGE  
analysis.  As  shown  earlier,  the  supernatant  of  high  molecular  weight  hyaluronan  
treated  samples  contained  hyaluronan  of  differing  weights  ranging  from  the  
normal  high  weight  to  smaller  fragments.  Thus,  it  is  possible  that  the  Th17  cells  
were  able  to  cleave  the  hyaluronan  using  a  hyaluronidase.  There  are  several  
hyaluronidases  known  to  exist  in  the  body:  hyaluronidase  1,  2,  and  3  
(Lepperdinger  et  al.,  1998).    Previous  research  in  oligodendrocyte  progenitor  
(OPC)  cells  has  revealed  a  similar  mechanism  in  which  hyaluronidases  are  
secreted  to  cleave  hyaluronan,  which  then  signals  through  TLR2  (Miranda-­
Hernandez  &  Baxter,  2013).  However,  the  researchers  found  that  hyaluronan  
signaling  in  OPCs  downregulated  cell  differentiation.  Other  research  
hypothesized  that  TLR2  signaling  produces  Th17  specific  factors,  so  those  same  
factors  may  downregulate  OPC  differentiation  (Reynolds  &  Dong,  2013).  We  
considered  it  was  hyaluronidase  2  (Hyal2)  specifically  because  we  knew  it  was  
likely  expressed  in  T-­cells  and  it  showed  high  specificity  for  high  molecular  
weight  hyaluronan  (Lepperdinger  et  al.,  1998;;  Jiang  et  al.,  2011).  Thus,  our  new  





secreted  Hyal2  into  low  molecular  weight  hyaluronan  which  then  signals  through  
TLR2  to  upregulate  Th17  differentiation.  
  If  this  hypothesis  is  correct,  Th17  cells  could  form  a  positive-­feedback  
loop:  greater  concentrations  of  low  molecular  weight  hyaluronan  would  lead  to  
greater  Th17  differentiation,  which  in  turn  would  increase  hyaluronidase  2  
expression,  thereby  resulting  in  higher  concentrations  of  low  molecular  weight  
hyaluronan.  This  process  would  have  the  potential  to  be  useful  in  cases  of  injury,  
or  even  infection  in  tissues  containing  hyaluronan  by  increasing  a  Th17  
response.  However,  this  reaction  could  also  be  harmful  in  cases  where  there  is  
an  autoimmune  inflammatory  response.  This  is  similar  to  IL-­23  signaling  in  Th17  
cells;;  Il-­23,  expressed  by  dendritic  cells,  stimulates  pathogenic  Th17  
differentiation  (Rostami  &  Ciric,  2013).  Pathogenic  Th17  cells  then  express  
GMCSF,  thereby  inducing  dendritic  cells  or  other  APCs  to  release  more  IL-­23  
and  stimulate  more  Th17  differentiation  (El-­Behi  et  al.,  2011).    It  is  important  to  
note  that  an  antigen,  a  costimulatory  molecule  such  as  low  molecular  weight  
hyaluronan,  and  polarizing  cytokines  are  needed  to  initiate  Th17  differentiation  
(Jin  et  al.,  2012).  Only  after  Th17  cells  are  present  will  Hyal2  be  secreted,  and  
hyaluronan  digestion  occur.  Thus,  this  process  will  not  occur  without  some  initial  
injury,  infection,  or  other  antigen  presentation.    
Further  evidence  to  support  the  above  explanations  comes  from  results  
obtained  with  qPCR  and  ELISA.  Both  show  some  of  the  same  trends  as  was  
seen  with  the  flow  cytometry  data.  Essentially  we  saw  higher  expression  of  IL-­





There  are  some  differences  between  some  of  the  samples,  however;;  for  
example,  the  low  concentration  high  molecular  weight  hyaluronan  showed  the  
least  amount  of  upregulation  with  flow  cytometry,  but  the  highest  IL-­17A  mRNA  
expression.    
Some  of  the  differences  in  the  trends  we  observed  could  be  attributable  to  
the  different  forms  of  cytokine  expression  we  measured.  We  used  flow  cytometry  
to  analyze  intracellular  cytokines  protein  expression,  whereas  qPCR  was  used  to  
measure  cytokine  mRNA  relative  expression  and  ELISA  to  measure  extracellular  
cytokine  protein  concentration.  Flow  cytometry  and  qPCR  are  both  measured  on  
a  per  cell  basis,  while  ELISA  measures  total  protein  concentration,  so  differences  
in  cell  proliferation  across  conditions  could  impact  the  ELISA  results.  Different  
factors  such  as  mRNA  transcription  time  and  protein  stability  also  lead  to  
discrepancies  between  mRNA  and  protein  expression  trends  (Vogel  &  Marcotte,  
2013).  
However,  we  also  should  consider  that  cells  were  taken  for  analysis  when  
the  intracellular  cytokine  expression  was  optimal,  or  had  the  largest  differences  
between  conditions,  for  our  Th17  control.  Given  that  we  have  to  wait  for  mRNA  to  
be  translated  into  protein  to  be  analyzed  by  flow  cytometry,  and  then  wait  for  the  
protein  to  be  secreted  into  the  supernatant  to  be  analyzed  by  ELISA,  the  optimal  
mRNA  or  extracellular  cytokine  expression  would  not  have  been  at  the  same  
time  as  optimal  intracellular  cytokine  expression.  Since,  as  discussed  above,  
Hyal2  will  not  be  expressed  until  some  naïve  cells  have  differentiated  into  Th17,  





and  the  control/low  molecular  weight  samples.  This  could  be  one  possible  
explanation  for  the  discrepancies  in  results  between  the  high  molecular  weight  
qPCR  and  ELISA  data:  the  high  molecular  weight  samples  were  at  the  point  
where  IL-­17A  mRNA  expression  was  optimal,  but  not  protein  expression.    
More  evidence  to  support  this  time  delay  phenomenon,  and  thus  our  
hypothesis,  can  be  seen  with  the  RORγt  qPCR  results.  As  explained  previously,  
RORγt  is  one  of  several  transcription  factors  necessary  to  induce  Th17  
differentiation  (Louten  et  al.,  2009).  The  highest  RORγt  expression  was  in  the  
high  molecular  weight  samples,  indicating  that  the  cells  were  actively  
differentiating.  In  contrast,  the  control  and  low  molecular  samples  had  lower  
levels  of  expression,  indicating  that  the  bulk  of  their  differentiation  was  complete.    
We  also  saw  a  similar  trend  of  Th17  differentiation  upregulation  in  the  
TLR2-­/-­  cells,  as  was  seen  in  the  WT,  which  we  did  not  expect  given  our  
hypothesis.  If  hyaluronan  only  signaled  through  TLR2  for  differentiation  and  
proliferation,  we  would  not  have  expected  to  have  seen  Th17  differentiation  
upregulation  in  TLR2-­/-­  cells.  Given  that  the  removal  of  TLR2  resulted  in  a  
reduction  of  Th17  differentiation,  there  is  evidence  that  hyaluronan  signals  
through  TLR2.  Numerous  other  studies  also  found  that  hyaluronan  signals  
through  TLR2  in  various  other  cell  types  (Sloane  et  al.,  2010;;  Shimada  et  al.,  
2008).  For  example,  Scheiber  et  al.  (2006)  found  that  low  molecular  weight  
hyaluronan  signals  through  TLR2  to  induce  inflammatory  cytokine  production  in  
macrophages  and  dendritic  cells.  However,  the  researchers  also  found  that  high  





looking  at  expression  of  TNFα,  a  cytokine  not  produced  by  naïve  T-­cells,  so  it  is  
unknown  whether  signaling  in  naïve  T-­cells  would  be  affected  in  the  same  way.    
It  is  most  likely  that  hyaluronan  signals  through  multiple  receptors,  which  
is  why  we  still  see  some  upregulation  in  TLR2-­/-­  T-­cells.  Hyaluronan  is  unique,  
because  most  TLR2  ligands  are  bacterial  lipoproteins  that  do  not  signal  through  
multiple  receptors  (Parham,  2009).  However,  hyaluronan  signals  through  a  
variety  of  receptors  such  as  CD44  and  LYVE-­1  (Hernandez-­Pedro  et  al.,  2013).  
The  study  by  Scheiber  et  al.  (2006)  also  found  that  low  molecular  weight  
hyaluronan  stimulation  on  dendritic  cells  was  CD44  independent;;  that  may  or  
may  not  be  true  in  T-­cells  as  well.  Th17  cells  do  express  CD44,  so  that  is  the  
most  likely  receptor  for  hyaluronan  to  signal  through  in  addition  to  TLR2.    
We  did  not  see  a  difference  in  the  flow  cytometry  results  between  low  and  
high  molecular  weight  hyaluronan  conditions  in  the  TLR2-­/-­  cells.  This  may  
indicate  that  the  other  receptor,  CD44,  binds  to  both  low  and  high  molecular  
weight  hyaluronan  and  promotes  upregulation,  and  so  the  Hyal2  does  not  play  a  
significant  role  here  like  it  does  with  TLR2.  However,  the  qPCR  data  show  
substantial  differences  between  the  high  concentration  high  and  low  molecular  
weight  conditions.  Thus,  the  time  delay  discussed  above  may  still  have  been  
playing  a  role,  offering  evidence  that  Hyal2  is  involved  with  this  process.  
Furthermore,  it  has  been  discussed  previously  that  while  both  molecular  weights  
may  bind  CD44,  there  is  a  difference  in  avidity  as  well  as  other  factors  that  may  
alter  downstream  signaling.  Cyphert  et  al.  (2015)  review  the  topic,  noting  that  





receptors  to  cluster,  which  is  in  turn  dependent  on  hyaluronan  size,  cell  
activation,  and  cell  type.  As  interesting  as  this  is,  the  effects  of  hyaluronan  
signaling  through  CD44  to  upregulate  Th17  differentiation  were  outside  the  scope  
of  this  study.  To  exclude  the  effects  of  CD44  signaling,  and  determine  the  role  of  
TLR2  signaling  alone,  we  used  the  neutralizing  αCD44  antibody  treatment  
(discussed  later).    
Overall,  figure  13  shows  the  revised  hypothesis  for  hyaluronan  signaling  in  
Th17  cells,  including  the  role  of  Hyal2  and  CD44.  In  summary,  low  molecular  
weight  hyaluronan  signals  through  both  CD44  and  TLR2  to  upregulate  Th17  
differentiation.  The  mature  Th17  cell  produces  Hyal2,  which  digests  high  
molecular  weight  hyaluronan  to  low  molecular  weights,  which  then  cycle  back  to  
upregulate  Th17  differentiation  again.    
Viability  Assay    
The  viability  assay  supports  the  assertion  that  hyaluronan  signaling  
upregulated  Th17  differentiation  and  proliferation.  Interestingly,  the  highest  
number  of  living  cells  was  in  the  high  molecular  weight  hyaluronan  samples,  and  
not  in  the  low  molecular  weight  samples  which  had  the  highest  differentiation.  
This  may  also  be  explained  by  the  time  delay  we  observed  above:  if  the  high  
molecular  weight  samples  were  delayed,  there  would  be  greater  differentiation  at  
the  time  at  which  the  cells  were  taken  for  analysis,  and  actively  differentiating  
cells  would  be  less  likely  to  die.    
However,  this  assay  does  not  provide  evidence  for  the  role  of  TLR2  in  





percentages  of  Th17  cells  and  apoptotic  (7-­AAD+AnnexinV+)  cells.  One  possible  
explanation  is  that  this  assay  measured  the  number  of  dying  cells,  and  the  
number  of  proliferating  cells  and  dying  cells  might  not  be  proportionate  in  this  
system.  The  proliferating  cells  may  be  proliferating  at  different  rates  in  the  
different  samples,  given  that  we  have  a  time  delay  between  our  high  and  low  
molecular  weight  hyaluronan  samples.  To  determine  if  this  is  the  case,  we  could  
use  a  proliferation  assay  and  compare  to  the  viability  assay  results.  Other  
studies,  such  as  the  one  reported  by  Liu  et  al.  (2012),  used  a  tritium  proliferation  
assay  to  measure  cell  proliferation  directly.  In  this  assay,  tritium  atoms  are  
incorporated  into  DNA  of  developing  cells,  and  the  end  cell  DNA  radioactivity  is  
measured  to  determine  the  number  of  cells  divisions,  which  could  show  
differences  between  WT  and  TLR2-­/-­  groups.  Alternatively,  we  had  not  excluded  
CD44  signaling,  which  could  also  be  driving  cell  proliferation  (Baaten  et  al.,  
2010).  Either  way,  the  results  of  this  assay  were  consistent  with  the  results  of  the  
differentiation  assay.  
Anti-­CD44  Treatment  
As  discussed  above,  the  differentiation  assay  shows  evidence  of  
hyaluronan  signaling  in  the  TLR2-­/-­  cells,  likely  through  CD44.  To  determine  if  
the  upregulation  of  Th17  differentiation  was  caused  by  hyaluronan  signaling  
through  TLR2,  we  used  αCD44  antibodies  to  block  all  CD44  signaling  which  
could  be  producing  a  similar  effect.  Although  the  αCD44  treated  cells  
experienced  heavy  cell  death,  they  still  displayed  an  upregulation  of  Th17  





antibody  was  insufficient  to  completely  block  CD44  signaling,  but  an  increase  in  
the  antibody  concentration  may  have  been  toxic  to  the  cells.  This  is  not  entirely  
surprising;;  CD44  signaling  is  not  essential  for  the  survival  of  Th17  cells,  but  it  is  
known  to  participate  in  the  control  of  cell  expansion  (Baaten  et  al.,  2010).  Also,  
sodium  azide  or  other  chemicals  in  the  antibody  solution  could  have  damaged  
the  cells.  To  the  best  of  our  knowledge,  no  other  studies  attempted  to  use  this  
antibody  on  living  cells,  so  it  cannot  be  determined  if  this  is  an  issue  with  the  
antibody  or  with  the  lack  of  CD44  signaling.    
Furthermore,  it  appears  that  the  WT  cells  used  for  this  experiment  were  
compromised,  as  indicated  by  our  WT  no  antibody  conditions  which  did  not  follow  
previously  observed  trends.  Multiple  experiments  conducted  with  the  same  pool  
of  mice  at  the  same  time  showed  irregular  results  and  increased  cell  death.  We  
believe  there  may  have  been  health  issues  with  the  WT  mice  we  used.  We  have  
not  confirmed  any  health  issues  with  our  original  mice,  but  because  switching  to  
commercially  available  WT  mice  corrected  the  irregularities  in  other  experiments,  
we  are  reasonably  certain  this  was  the  problem.  However,  the  TLR2-­/-­  mice  did  
not  appear  to  have  the  same  health  issues,  and  thus  the  TLR2-­/-­  data  were  valid.  
This  may  also  be  why  there  was  less  cell  death  in  the  TLR2-­/-­  antibody  treated  
conditions;;  the  WT  cells  were  already  unhealthy  and  so  the  antibody  stressed  
them  more  and  increased  cell  death.  However,  there  was  still  significant  cell  
death  in  the  TLR2-­/-­  cells,  indicating  that  the  antibody  concentration  was  indeed  





As  it  stands  presently,  we  cannot  provide  a  definitive  role  for  TLR2  
signaling  in  hyaluronan  mediated  Th17  differentiation  upregulation.  We  need  to  
repeat  this  experiment  with  a  higher  antibody  concentration  and  healthier  cells.  If,  
as  we  suspect,  these  conditions  are  still  too  stressful,  we  would  need  to  then  find  
another  route  to  block  CD44  signaling.  One  possibility  would  be  crossing  TLR2-­/-­  
mice  with  CD44  knockout  mice,  which  do  not  express  CD44,  and  isolate  naïve  
cells.  These  cells  would  not  possess  CD44  or  TLR2,  and  thus  could  be  
compared  to  CD44KO  cells  in  a  differentiation  assay  to  examine  the  effect  of  
hyaluronan  signaling  through  TLR2  exclusively.  
Retroviral  Transfection  
   Based  on  our  hypothesis,  Hyal2  digests  high  molecular  weight  hyaluronan  
into  lower  molecular  weight  fragments,  which  then  signal  through  TLR2  to  
upregulate  Th17  differentiation.  If  we  overexpress  Hyal2,  as  we  did  in  our  
retroviral  transfection,  we  would  then  expect  to  see  increased  Th17  differentiation  
compared  to  control,  non-­overexpressed  samples.  Despite  the  successful  
transfection,  indicated  by  the  high  number  of  GFP+  cells,  most  of  the  cells  died.  
As  such,  the  cells  were  unable  to  produce  significant  amounts  of  Hyal2  and  
proliferate  before  dying.  Consequently,  there  were  no  observable  trends.  The  
SDS-­PAGE  analysis  showed  no  more  digestion  in  the  retroviral  transfection  than  
it  did  in  the  initial  SDS-­PAGE  analysis  of  the  differentiation  assay,  confirming  that  






Presumably,  the  high  cell  death  was  caused  by  the  stressful  conditions  of  
the  retroviral  transfection:  to  determine  the  role  of  Hyal2,  we  would  need  to  alter  
the  conditions  of  the  transfection  such  that  the  cells  would  be  able  to  survive  and  
proliferate.  The  control  transfection,  using  the  empty  vector,  shows  the  same  
high  cell  death,  indicating  this  is  not  a  result  of  the  upregulation  of  Hyal2.  This  is  
difficult,  because  there  are  toxic  compounds  such  as  polybrene,  and  also  
mechanical  stresses  during  centrifugation  that  are  essential  to  the  transfection  
that  may  injure  the  cells.  One  factor  we  could  change  would  be  to  allow  for  more  
time  between  naïve  T-­cell  plating  and  transfection;;  if  the  cells  are  not  activated  
before  exposure  to  the  virus,  they  would  be  much  more  likely  to  die  (Berggren,  
2012).    
Should  we  be  unable  to  adjust  the  retroviral  transfection  sufficiently  to  
enable  cell  survival,  we  could  add  additional  Hyal2  directly  to  the  cells.  However,  
there  is  no  murine  Hyal2  commercially  available,  so  the  enzyme  may  have  
unforeseen  interactions  in  murine  cells.  Alternatively,  if  we  find  that  the  
overexpression  of  Hyal2,  and  not  the  transfection  itself,  was  causing  cell  death,  
we  could  try  using  another  vector  to  suppress  Hyal2  expression.  This  vector  
would  encode  short  hairpin  RNA  (shRNA)  that  would  attach  to  the  Hyal2  gene  
and  prevent  translation  of  mRNA.  Then,  we  could  examine  whether  the  
upregulation  of  Th17  differentiation  by  high  molecular  weight  hyaluronan  is  








As  discussed  previously,  one  clinical  aspect  of  this  research  is  to  identify  a  
self-­molecule  that  could  aggravate  the  sterile  inflammation  encountered  in  
autoimmune  diseases  such  as  MS.  Previous  research  has  shown  that  TLR2  
ligands  such  as  peptidoglycan  can  upregulate  Th17  differentiation,  and  Th17  
cells  are  heavily  implicated  in  MS  (Reynolds  et  al.,  2010).  Hyaluronan  is  unique  
because  it  is  an  abundant  self-­molecule.  Furthermore,  if  the  positive  feedback  
loop  we  speculated  about  is  possible,  then  hyaluronan  would  be  more  potent  
than  other  TLR2  ligands  because  it  is  self-­replenishing.  The  results  of  this  study  
provide  preliminary  evidence  for  this  role  of  hyaluronan,  but  require  greater  work  
to  confirm  the  trends  are  significant.  We  need  to  repeat  the  unreliable  assays  
with  the  suggested  revisions  to  verify  the  results,  as  well  as  confirm  the  presence  
of  Hyal2;;  the  retroviral  transfection  would  provide  evidence  for  its  presence.  To  
explicitly  show  Hyal2’s  presence,  we  could  perform  a  western  blot  on  sample  
supernatant;;  this  procedure  would  allow  us  to  visualize  specific  proteins  such  as  
Hyal2,  allowing  us  to  confirm  its  presence.  Assuming  we  verify  everything  and  
our  results  are  as  expected,  we  should  continue  our  work  by  confirming  the  same  
trends  hold  true  with  in  vivo  experiments.  
One  avenue  of  future  research  could  be  to  confirm  if  hyaluronan  will  
upregulate  Th17  differentiation  in  MS  specifically.  To  do  this,  we  could  use  
hyaluronan  in  a  murine  model  of  MS,  EAE.  In  an  EAE  experiment,  mice  are  
injected  with  myelin  oligodendrocyte  glycoprotein  (MOG),  which  is  a  component  





et  al.,  2010).  The  CD4+  T-­cells  are  then  removed  from  these  mice,  allowed  to  
differentiate  and  proliferate,  then  injected  into  Rag1  mice,  which  lack  any  T-­cells.  
These  Rag1  mice  then  develop  EAE,  which  is  scored  by  the  extent  of  paralysis.  
To  determine  the  effect  of  hyaluronan,  we  could  incubate  the  CD4+  cells  with  
hyaluronan  before  injection  into  the  Rag1  mice.  We  would  expect  to  see  higher  
Th17  differentiation  and  proliferation,  which  would  lead  to  greater  disease  
progression  as  measured  by  a  higher  clinical  score,  in  the  hyaluronan  treated  
samples.      
More  interestingly,  we  could  examine  the  role  of  Hyal2  to  determine  
whether  the  digestion  of  hyaluronan  is  physiologically  relevant.  To  do  this,  we  
would  essentially  repeat  the  EAE  experiment  detailed  above,  but  instead  of  
incubating  the  cells  with  hyaluronan  during  expansion,  we  would  conduct  a  
retroviral  transfection  with  the  Hyal2  vector,  then  add  hyaluronan  before  injecting  
into  Rag1  mice.  This  assumes  that  we  will  be  able  to  revise  the  retroviral  
transfection  conditions  sufficiently  to  allow  the  cells  to  survive,  but  that  is  likely  to  
be  possible.  The  results  of  this  experiment  would  help  determine  if  Hyal2  does  
play  a  role  in  MS  development;;  for  the  in  vitro  experiments  we  conducted,  we  
had  comparatively  high  hyaluronan  levels  and  no  known  hyaluronidase  inhibitors,  
which  may  not  mimic  conditions  in  the  body.    
Once  we  have  confirmed  that  we  still  can  observe  these  effects  in  vivo,  we  
could  then  examine  the  mechanism  behind  TLR2  signaling  that  leads  to  Th17  
differentiation.  We  have  conducted  some  research  on  this  topic,  focusing  on  the  





binding  protein  7  (ChD7)  in  the  process.  Once  the  mechanism  is  fully  elucidated,  
clinical  research  can  begin  looking  for  target  molecules  to  inhibit  so  as  to  stop  
MS  development  and  progression.  Finally,  research  has  shown  a  role  for  TLR2  
activation  in  other  Th17  driven  autoimmune  disorders,  such  as  rheumatoid  
arthritis,  so  we  could  also  examine  if  hyaluronan  plays  a  role  there  as  well  
(McGarry  et  al.,  2015).  
Conclusion  
   Overall  our  study  was  conducted  to  show  that  low  molecular  weight  
hyaluronan  signals  through  TLR2  to  upregulate  Th17  differentiation  and  
proliferation.  After  reviewing  the  differentiation  assay  results,  we  adjusted  our  
hypothesis  to  include  the  role  of  Hyal2,  which  digests  high  molecular  weight  
hyaluronan  into  a  lower  molecular  weight.  Figure  13  shows  our  adjusted  
hypothesis  containing  roles  for  both  Hyal2  and  CD44  in  hyaluronan  signaling  for  
Th17  differentiation.  Our  results  provide  evidence  for  the  role  of  hyaluronan  and  
TLR2,  but  more  experimental  work  must  be  conducted  to  confirm  the  role  of  
Hyal2.  Both  low  and  high  molecular  weight  hyaluronan  were  shown  to  upregulate  
Th17  differentiation,  and  the  removal  of  TLR2  impaired  Th17  differentiation  
slightly,  indicating  TLR2  is  but  one  of  multiple  receptors  that  hyaluronan  signals  
through.  However,  experimental  difficulties  prevented  us  from  obtaining  sufficient  
evidence  for  the  role  of  Hyal2.  This  work  illuminates  a  possible  self-­molecule  that  








Figure  13.  A  diagram  of  the  revised  hypothesis.  1.  A  self-­antigen-­MHC  ll  complex  
signals  through  the  TCR  and  CD4,  and  stimulatory  cytokines  activate  the  naïve  
T-­cell.  2.  The  naïve  T-­cell  differentiates  into  a  mature  Th17,  which  releases  pro-­
inflammatory  cytokines  and  Hyal2.  3.  Hyal2  digests  high  molecular  weight  
hyaluronan  in  the  supernatant.  4.  The  low  molecular  weight  hyaluronan  signals  
through  TLR2  and  CD44  on  an  activated  naïve  T-­cell  to  upregulate  Th17  
differentiation,  forming  a  positive  feedback  loop.      
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